Search Results for: covid-19
Articles
Valneva Successfully Completes Pivotal Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate March 8, 2022
Valneva SE recently announced the successful completion of the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553....Evonik Increases Global Supply of Pharma-Grade Plant-Derived Cholesterol for mRNA Vaccines & Gene Therapies March 4, 2022
Evonik has boosted its supply of plant-derived cholesterol, one of the most critical components for the manufacture of mRNA vaccines and gene therapies. The large-scale production of….
Aeterna Zentaris Announces Notice of Allowance for US Patent Covering AEZS-150 for the Potential Treatment of Chronic Hypoparathyroidism March 2, 2022
Aeterna Zentaris Inc. recently announced that its licensor, The University of Sheffield, has received a notice of allowance from the USPTO for its patent application No. 16/608,611…..
MARKET LANDSCAPE - The Future of Cancer Care Post-Pandemic: What Doctors, Patients, and the Healthcare Industry at Large Should Expect March 1, 2022
Angelos Stergiou, PhD, explains how the COVID-19 pandemic saw failures in the healthcare delivery system not only in general medicine, but also specifically in oncology. At the same time, several opportunities came to light during such a difficult, frightening moment, bringing a number of large- and small-scale innovations forth.
Durable & Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial February 28, 2022
Evelo Biosciences, Inc. recently announced data from the post-treatment follow-up (Part B) of its Phase 2 trial of EDP1815 in...Genevant Sciences & Arbutus Biopharma File Patent Infringement Lawsuit Against Moderna February 28, 2022
Genevant Sciences and Arbutus Biopharma Corporation recently filed a lawsuit in the US District Court for the District of Delaware...TFF Pharmaceuticals Announces Inhaled Niclosamide Significantly Inhibits Viral Replication of the Omicron Variant of SARS-CoV-2 February 24, 2022
TFF Pharmaceuticals, Inc. recently announced that results from its recently completed in vitro neutralization and viral replication assays indicate that the company’s inhaled niclosamide product candidate completely….
Moderna Initiates Phase 3 Portion of Pivotal Trial for mRNA Respiratory Syncytial Virus Vaccine Candidate February 22, 2022
Moderna, Inc. recently announced the Data and Safety Monitoring Board (DSMB) for the RSV program has endorsed the start of...Veru Announces the Presentation of Updated Data From Phase 1b/2 Sabizabulin Study in Men With Metastatic Castration Resistant Prostate Cancer February 17, 2022
Veru Inc. recently announced that updated clinical data from the positive Phase 1b/2 study of sabizabulin in 80 men with...Revive Therapeutics Receives FDA Orphan Drug Designation February 16, 2022
Revive Therapeutics Ltd. recently announced the US FDA has granted Orphan Drug Designation (ODD) for Bucillamine for the prevention of...Pardes Biosciences Presents Interim Clinical Data From Ongoing PBI-0451 Phase 1 Trial February 14, 2022
Pardes Biosciences, Inc. recently announced interim clinical data from its ongoing PBI-0451 Phase 1 trial in healthy adult volunteers has...Cidara Therapeutics Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention & Treatment of Influenza February 14, 2022
Cidara Therapeutics, Inc. recently announced the US FDA has accepted its Investigational New Drug (IND) application for its lead flu...IsoPlexis’ Immune Monitoring Helps Identify Early Factors of Long COVID in Cell Publication February 10, 2022
IsoPlexis Corporation recently announced the publication of a study in Cell, led by the Institute for Systems Biology and Seattle...CureVac Doses First Participant in Phase 1 Study With Multivalent Influenza Vaccine Candidate Based on Second-Generation mRNA Backbone Developed in Collaboration With GSK February 10, 2022
CureVac N.V. recently announced it has dosed the first participant in a Phase 1 study of its seasonal influenza second-generation...Xanadu Bio Obtains Licenses & Options to Novel Platform Technologies From Yale University to Develop Intranasal SARS CoV-2 mRNA Vaccine Booster February 8, 2022
Xanadu Bio recently announced a broad exclusive license agreement from Yale University for a next-generation polymeric nanoparticle delivery platform known as PACE. Additionally, the company has executed….
Ocuphire Completes Enrollment in MIRA-3 Pivotal Phase 3 Clinical Trial February 8, 2022
Ocuphire Pharma, Inc. recently announced it has completed enrollment in MIRA-3, the second Phase 3 FDA registration trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically….
CDMO INNOVATION - How a Global CDMO Puts Innovation at the Forefront of its Business Strategy February 7, 2022
Kai Vogt, Senior Vice President Corporate Development/Legal/Corporate Compliance/IT, Vetter, explains how a global CDMO puts innovation at the forefront of its business strategy.
Valneva & Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate February 7, 2022
Valneva SE and Pfizer Inc. recently reported further positive Phase 2 data for their Lyme disease vaccine candidate, VLA15. Based on these new results….
Pardes Biosciences Announces FDA Clearance of IND Application for Oral Antiviral Drug Candidate for the Treatment & Prevention of SARS-CoV-2 Infections February 3, 2022
Pardes Biosciences, Inc. recently announced its Investigational New Drug (IND) application for PBI-0451 has been cleared by the US FDA....Arch Scientists Publish Data on the Mechanism of Action & Efficacy of Lead Drug Candidate LSALT Peptide in the Prevention of Acute Kidney Injury February 3, 2022
Arch Biopartners Inc. recently announced a scientific team led by Dr. Daniel Muruve at the University of Calgary, and their...
